RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
International Stem Cell Stock

International Stem Cell Net Income 2025

International Stem Cell Net Income

-209,000 USD

Ticker

ISCO

ISIN

US4603782016

In 2025, International Stem Cell's profit amounted to -209,000 USD, a 59.54% increase from the -131,000 USD profit recorded in the previous year.

The International Stem Cell Net Income history

YEARNET INCOME (undefined USD)
2024-
2023-
2022-
2021-
2020-
2019-
2018-
2017-
2016-
2015-
2014-
2013-
2012-
2011-
2010-
2009-
2008-
2007-
2006-

International Stem Cell Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into International Stem Cell, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by International Stem Cell from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects International Stem Cell’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of International Stem Cell. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into International Stem Cell’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing International Stem Cell’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on International Stem Cell’s growth potential.

International Stem Cell Revenue, EBIT and net profit per share

DateInternational Stem Cell RevenueInternational Stem Cell EBITInternational Stem Cell Net Income
20249.09 M undefined-68,000 undefined-209,000 undefined
20237.79 M undefined-663,000 undefined-131,000 undefined
20228.18 M undefined-183,000 undefined-331,000 undefined
20217.18 M undefined-1.92 M undefined-899,000 undefined
20207.13 M undefined-2.82 M undefined-2.72 M undefined
20199.47 M undefined-4.19 M undefined-4.27 M undefined
201811.09 M undefined-3.47 M undefined-2.13 M undefined
20177.46 M undefined-4.94 M undefined-6.07 M undefined
20167.17 M undefined-4.85 M undefined-1.08 M undefined
20157.55 M undefined-4.56 M undefined-2.64 M undefined
20147.02 M undefined-8.68 M undefined-12.48 M undefined
20136.15 M undefined-7.41 M undefined-10.48 M undefined
20124.57 M undefined-9.62 M undefined-11.34 M undefined
20114.53 M undefined-11.36 M undefined-9.6 M undefined
20101.57 M undefined-10.46 M undefined-14.28 M undefined
20091.12 M undefined-7.2 M undefined-12.17 M undefined
2008500,000 undefined-5.53 M undefined-8.15 M undefined
200740,000 undefined-6.07 M undefined-6.07 M undefined
20060 undefined-5.72 M undefined-6.58 M undefined

International Stem Cell stock margins

The International Stem Cell margin analysis displays the gross margin, EBIT margin, as well as the profit margin of International Stem Cell. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for International Stem Cell.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the International Stem Cell's sales revenue. A higher gross margin percentage indicates that the International Stem Cell retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the International Stem Cell's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the International Stem Cell's total revenue generated. When comparing the revenue margin year over year, investors can gauge the International Stem Cell's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the International Stem Cell. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the International Stem Cell's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

International Stem Cell Margin History

International Stem Cell Gross marginInternational Stem Cell Profit marginInternational Stem Cell EBIT marginInternational Stem Cell Profit margin
202458.57 %-0.75 %-2.3 %
202359.16 %-8.51 %-1.68 %
202260.04 %-2.24 %-4.05 %
202159.1 %-26.77 %-12.53 %
202060.98 %-39.53 %-38.22 %
201958.48 %-44.21 %-45.03 %
201863.31 %-31.33 %-19.22 %
201771.54 %-66.28 %-81.4 %
201672.87 %-67.7 %-15.06 %
201572.77 %-60.44 %-34.9 %
201473.51 %-123.7 %-177.83 %
201373.17 %-120.49 %-170.41 %
201272.21 %-210.5 %-248.14 %
201164.24 %-250.77 %-211.92 %
201053.5 %-666.24 %-909.55 %
200929.46 %-642.86 %-1,086.61 %
200874 %-1,106 %-1,630 %
200758.57 %-15,175 %-15,175 %
200658.57 %0 %0 %

International Stem Cell Aktienanalyse

What does International Stem Cell do?

International Stem Cell Corp (ISCO) is a biotechnology company founded in 2005 and headquartered in Carlsbad, California. It specializes in the development and manufacture of stem cell products for therapeutics and research purposes. ISCO specializes in the production of "human parthenogenetic stem cells" (hpSCs). This means that they produce stem cells from human egg cells that can replicate without fertilization by sperm. The company is a leader in this field and has filed over 80 patents worldwide. ISCO has various business areas, including life science research, therapeutics, dermatology, and animal health. The company partners with various industries, including academic institutions, pharmaceutical and biotechnology companies, and government agencies. One of their biggest partnerships is with the Chinese company Sino Biopharmaceuticals. ISCO offers a variety of products, including in vitro diagnostics for testing genetic diseases such as Huntington's and food allergies. However, the diagnostics division of the company is a small department primarily focused on research and development purposes. ISCO also has a dermatology division called Lifeline Skin Care, which manufactures skincare products based on human stem cells. These products have been developed for improving skin texture and reducing scars. Lifeline Skin Care is a luxury brand for skincare products currently sold in over 15 countries worldwide. In terms of animal health, ISCO recently launched a new division called Lifeline Animal Health. They are developing animal therapeutics based on hpSCs. The company has already developed the first animal therapeutic for dogs approved for the treatment of hip dysplasia. However, ISCO primarily focuses on the development of therapeutics for human stem cells. The company aims to be a global leader in the development of stem cell therapeutics. Their first product, CytoCor for heart disease, is already in clinical phase 1b/2a. The drug is intended to help reduce damage after a heart attack and improve heart function. ISCO also plans to develop therapeutics for other indications, including Alzheimer's disease, based on hpSCs. The company has a strong partnership with the California Institute for Regenerative Medicine, which focuses on stem cell research and their use in medicine. ISCO is a leading company in stem cell research and development. They have a unique approach to stem cell production and offer a variety of products and services for various industries. The company aims to develop groundbreaking stem cell therapeutics and change the way diseases are treated. International Stem Cell ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Net Income Details

Understanding International Stem Cell's Profit Margins

The profit margins of International Stem Cell represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of International Stem Cell's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.

Year-to-Year Comparison

Evaluating International Stem Cell's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.

Impact on Investments

International Stem Cell's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.

Interpreting Profit Fluctuations

When International Stem Cell’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.

Frequently Asked Questions about International Stem Cell stock

How much profit has International Stem Cell made this year?

International Stem Cell has made -209,000 USD this year.

How has the profit developed compared to last year?

The profit has increased by 59.54% compared to last year increased

What impact do the earnings have on the shareholders?

An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.

How does International Stem Cell publish its earnings?

International Stem Cell publishes its earnings in the form of quarterly or annual reports.

Which financial indicators are included in the quarterly or annual reports?

The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.

Why is it important for investors to know the earnings of International Stem Cell?

The profits of International Stem Cell are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.

How can one learn more about the earnings of International Stem Cell?

You can learn more about the earnings of International Stem Cell by reviewing the quarterly or annual reports or following the company presentations.

How much dividend does International Stem Cell pay?

Over the past 12 months, International Stem Cell paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, International Stem Cell is expected to pay a dividend of 0 USD.

What is the dividend yield of International Stem Cell?

The current dividend yield of International Stem Cell is .

When does International Stem Cell pay dividends?

International Stem Cell pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of International Stem Cell?

International Stem Cell paid dividends every year for the past 0 years.

What is the dividend of International Stem Cell?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is International Stem Cell located?

International Stem Cell is assigned to the 'Health' sector.

Wann musste ich die Aktien von International Stem Cell kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of International Stem Cell from 6/19/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 6/19/2025.

When did International Stem Cell pay the last dividend?

The last dividend was paid out on 6/19/2025.

What was the dividend of International Stem Cell in the year 2024?

In the year 2024, International Stem Cell distributed 0 USD as dividends.

In which currency does International Stem Cell pay out the dividend?

The dividends of International Stem Cell are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von International Stem Cell

Our stock analysis for International Stem Cell Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of International Stem Cell Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.